Triple-Pill Therapy Reduces Recurrent Stroke Risk After Intracerebral Hemorrhage

Secondary prevention after intracerebral hemorrhage is a significant clinical hurdle, as these patients remain at high risk for both recurrent bleeding and ischemic events [1]. While blood pressure reduction is the primary evidence-based intervention for stroke prevention, the most effective pharmacological strategy for maintaining targets in this population remains unclear [2]. Clinicians must balance the benefits of intensive therapy against the risk of adverse events, particularly in patients with small vessel disease or cerebral microbleeds [3, 4]. Despite the known benefits of antihypertensive therapy, many patients fail to reach goal pressures, suggesting a need for more effective delivery methods for secondary prevention [5]. A recent multinational trial now evaluates whether a specific combination strategy can improve these clinical outcomes.